AXGN

Business Context and Reporting Period

Company: LecTec Corporation (Note: Input metadata referenced "Axogen, Inc.", but the filing text identifies the registrant as LecTec Corporation).

Reporting Period: Fiscal year ended June 30, 1995.

Business Overview: LecTec designs, manufactures, and markets diagnostic and monitoring electrodes, conductive and non-conductive adhesive hydrogels, medical tapes, and therapeutic products. The company utilizes patented "solid state" electrode technology and solvent-free adhesives. Key product lines include Tracets diagnostic electrodes, SynCor monitoring electrodes, and various medical tapes. In April 1994, the company acquired a controlling 51% interest in Natus Corporation, a distributor of natural health and therapeutic products, and began consolidating its results.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 32% to $14.1 million, driven primarily by a 254% surge in therapeutic product sales (to $3.1 million) and a 22% increase in conductive product sales (to $7.3 million). Medical tape sales declined slightly by 3%.
• Profitability Decline: Despite revenue growth, net earnings dropped 76% to $154,000. This was primarily due to a 105% increase in Selling, General, and Administrative (SG&A) expenses to $3.75 million, largely attributable to the full-year consolidation of Natus Corporation and associated goodwill amortization.
• Expense Increases: Research and Development (R&D) expenses rose to $1.88 million (13% of revenue), up from $1.38 million in 1994, driven by clinical trials for a non-nicotine smoking cessation product.
• Liquidity: Cash and cash equivalents decreased by $1.34 million to $840,000. This reduction funded capital expenditures of $1.47 million (primarily a new therapeutic production line), increased inventory, and higher receivables.
• Customer Concentration: The number of active customers decreased from ~240 to ~150 as the company consolidated low-volume accounts. Burdick Corporation remained the largest customer, accounting for 14.6% of total revenues.

Guidance, Outlook, and Risks

• Outlook: Management expects international revenues to remain approximately the same as a percentage of total revenues but anticipates a shift toward domestic market opportunities. Gross margins are expected to improve in fiscal 1996 due to manufacturing efficiencies from a new medical tape production line and higher sales of therapeutic products.
• R&D Pipeline: The company is actively seeking a marketing partner for its non-nicotine smoking cessation product (cotinine) for fiscal 1996. Phase II clinical trials showed the product is effective in alleviating withdrawal symptoms with minimal abuse potential.
• Capital Resources: The company is debt-free with a $1 million annually renewable revolving line of credit (no outstanding balance). Management believes internally generated cash and the credit line are sufficient for anticipated growth.
• Risks:
  • Competition: Highly competitive markets with larger rivals (e.g., 3M) possessing greater financial resources.
  • Regulatory: Products are subject to FDA regulation; new drug delivery technologies require New Drug Application (NDA) approval.
  • Customer Concentration: Reliance on a few major customers (Burdick, Beiersdorf) for a significant portion of revenue.

Investor Verification Checklist

• Verify the sustainability of the 254% growth in therapeutic product sales and the success of the Natus Corporation integration.
• Confirm the timeline and terms for securing a marketing partner for the cotinine smoking cessation product.
• Monitor the impact of the new medical tape production line on gross margins in the upcoming fiscal year.
• Assess the risk associated with the reduction in active customer count and continued reliance on Burdick Corporation (14.6% of revenue).
• Review the cash burn rate relative to the $1 million credit line, given the significant capital expenditures in fiscal 1995.